Cumberland Pharmaceuticals (CPIX) CEO granted 100,000 stock options

Rhea-AI Filing Summary

Cumberland Pharmaceuticals Chairman and CEO A. J. Kazimi received a grant of stock options covering 100,000 shares of common stock at an exercise price of $2.8000 per share. After this award, he holds options for a total of 568,000 shares, reflecting compensation rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider KAZIMI A J

Role Chairman and CEO

Type	Security	Shares	Price	Value
Grant/Award	Options (right to buy)	100,000	$2.80	$280K

Holdings After Transaction: Options (right to buy) — 568,000 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAZIMI A J

(Last) (First) (Middle)

1600 WEST END AVE.

SUITE 1300

(Street)

NASHVILLE TENNESSEE 37203

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (right to buy)	$2.8	03/18/2026		A		100,000		03/18/2030	03/18/2036	Common Stock	100,000	$2.8	568,000	D

Explanation of Responses:

Remarks:

	A.J. Kazimi by /s/ John Hamm as attorney-in-fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Cumberland Pharmaceuticals (CPIX) disclose in this Form 4 filing?

Cumberland Pharmaceuticals reported that Chairman and CEO A. J. Kazimi received a grant of options for 100,000 shares at $2.8000 per share. These options are a compensation award rather than a market purchase of common stock.

How many options does Cumberland CEO A. J. Kazimi hold after this grant?

Following the reported grant, A. J. Kazimi holds options covering 568,000 shares of Cumberland Pharmaceuticals common stock. This total includes the newly awarded 100,000-share option grant disclosed in the Form 4 insider transaction report.

What are the key terms of the new Cumberland Pharmaceuticals (CPIX) option grant?

The new award gives A. J. Kazimi options on 100,000 shares of common stock with an exercise price of $2.8000 per share. The options list an exercise date in 2030 and expire in 2036, according to the filing details.

Is the Cumberland Pharmaceuticals CEO Form 4 transaction a stock purchase or compensation?

The Form 4 shows a grant coded as an acquisition (A) of derivative securities, indicating a compensation-related stock option award. It is not an open-market purchase or sale of Cumberland Pharmaceuticals common shares by the CEO.

What type of security is involved in the Cumberland Pharmaceuticals (CPIX) insider transaction?

The transaction involves derivative securities described as “Options (right to buy)” Cumberland Pharmaceuticals common stock. Each option grant relates to one underlying share, for 100,000 underlying shares in total at the specified exercise price.